



(11) **EP 1 560 821 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
19.05.2010 Bulletin 2010/20

(45) Date of publication and mention
of the grant of the patent:
24.03.2010 Bulletin 2010/12

(21) Application number: **03816120.4**

(22) Date of filing: **04.11.2003**

(51) Int Cl.:
C07D 401/06 (2006.01) A61K 31/47 (2006.01)

(86) International application number:
PCT/US2003/035201

(87) International publication number:
WO 2004/096982 (11.11.2004 Gazette 2004/46)

(54) **ANTIBACTERIAL AGENTS**
ANTIBAKTERIELLE WIRKSTOFFE
AGENTS ANTIBACTERIENS

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
LT LV

(30) Priority: **05.11.2002 US 423858 P**

(43) Date of publication of application:
10.08.2005 Bulletin 2005/32

(73) Proprietor: **Glaxo Group Limited**
Greenford
Middlesex
UB6 0NN (GB)

(72) Inventors:
• **AXTEN, Jeffrey, Michael**
Collegeville, PA 19426 (US)
• **MILLER, William, Henry**
Collegeville, PA 19426 (US)
• **SEEFELD, Mark, Antony**
Collegeville, PA 19426 (US)

(74) Representative: **Valentine, Jill Barbara et al**
GlaxoSmithKline
Corporate Intellectual Property (CN9.25.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:
WO-A1-00/21948

EP 1 560 821 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).